Conduit Pharmaceuticals Inc CDT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.10
- Day Range
- $3.05–3.17
- 52-Week Range
- $0.95–25.00
- Bid/Ask
- $3.08 / $3.17
- Market Cap
- $234.04 Mil
- Volume/Avg
- 5,588 / 32,654
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company’s current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor and renal transplant rejection. The Company’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.conduitpharma.com
Valuation
|
Metric
|
CDT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CDT
|
|---|---|
Quick Ratio | 2.35 |
Current Ratio | 3.18 |
Interest Coverage | −0.34 |
Quick Ratio
CDT
Profitability
|
Metric
|
CDT
|
|---|---|
Return on Assets (Normalized) | −123.80% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CDT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dcxzrhvdp | Blc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zdhdpjxvf | Ldwpsy | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bqxzzpfvk | Zbqbfd | $97.8 Bil | |
MRNA
| Moderna Inc | Gfhyqcdw | Tkjzn | $41.3 Bil | |
ARGX
| argenx SE ADR | Phkgtfdr | Zhwdp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nqvjllwh | Fzbs | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Snksssdbq | Kznwq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kvzdxlyxv | Gctvw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qqwqzsqpd | Wvqvv | $12.5 Bil | |
INCY
| Incyte Corp | Hqztnfbl | Gbpvdvs | $11.6 Bil |